Recent Updates — GANX
Gain Therapeutics appointed Jeanette Weidner as Vice President of Finance, Chief Financial Officer, and Principal Accounting Officer, effective October 28, 2026. Ms. Weidner brings over 18 years of accounting and finance experience in the life sciences sector, including prior roles at Senseonics Holdings and OncoC4. Her employment agreement includes a $275,000 annual base salary, a target incentive bonus of 35% of base pay, and an initial stock option grant for 130,000 shares vesting over four years. The company operates in the biopharmaceutical industry, focusing on the discovery and development of novel therapeutics.
Gain Therapeutics, Inc. announced the resignation of Gianluca Fuggetta as Senior Vice President of Finance and principal financial officer, effective September 30, 2026, to pursue other opportunities. The Board appointed current President and CEO Gene Mack as interim Chief Financial Officer, assuming duties as principal financial and accounting officer starting October 1, 2026, while continuing in his existing roles. Mr. Mack’s compensation remains unchanged, and the company is actively searching for a permanent replacement. Gain Therapeutics operates in the biotechnology industry, focusing on drug discovery.
Gain Therapeutics reported a second-quarter 2026 net loss of $0.11 per share, an improvement from the $0.19 loss in the prior-year period. Research and development expenses decreased to $2.1 million, while general and administrative costs rose slightly to $2.5 million. The company holds $13.1 million in cash as of June 30, 2026. Key operational highlights include FDA authorization of an Investigational New Drug application for rexaceract, enabling the start of Phase 2 clinical development expected in Q3 2026. Additionally, Dr. Joanne Taylor was promoted to Chief Scientific Officer and Terenzio Ignoni to Chief Operating Officer. Gain Therapeutics is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for neurodegenerative diseases.
Gain Therapeutics, Inc. announced that its current cash and cash equivalents are expected to fund operations into the second quarter of 2027. This funding includes the completion of the Phase 1b open-label extension in October 2026 and the initiation of a Phase 2 clinical study in the third quarter of 2026. Gain Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for neurological and other diseases.
Gain Therapeutics, Inc. announced on June 29, 2026, that the U.S. Food and Drug Administration (FDA) authorized its Investigational New Drug application for GT-02287. This authorization allows the company to initiate Phase 2 clinical development of GT-02287 for Parkinson's disease in the United States, Australia, and Europe. The company anticipates the initiation of the Phase 2a study of oral GT-02287 in participants with early Parkinson's disease during the third quarter of 2026. Gain Therapeutics, Inc. is a biotechnology company focused on the development of therapeutic candidates for neurological and neurological-related diseases.